Drug discovery to control and eradicate malaria

Malaria is a devastating disease affecting millions of people each year yet, surprisingly, apart from the artemisinin combination therapies (ACTs) there are relatively few effective treatments for Plasmodium falciparum and only one complete treatment for Plasmodium vivax. This talk will briefly summarize the work of Medicines for Malaria Venture (MMV) and its mission to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs in collaboration with international partners. MMV manages a significant antimalarial pipeline and this has been strengthened in recent years with the delivery of new products, new clinical candidates and early stage discovery projects. The talk will explain both the challenges that need to be overcome and the strategy adopted to control and eradicate the disease, including definitions of target product and candidate profiles necessary for asexual blood stage cures (including single dose combination treatment), transmission blocking, vivax and chemoprotection.

Biography

Brice Campo joined MMV in 2011. Before that, he worked with the Genomics Institute of the Novartis Foundation (GNF) in San Diego (USA) and Addex Pharmaceuticals S.A in Geneva (CH). Having worked in drug discovery for about 15 years, he has broad experience in molecular pharmacology as well as drug discovery in several disease areas such as Neuroscience, Metabolic Disease and Inflammation, working with teams that have successfully delivered clinical candidates. He has a PhD in Neuroscience and Immunology from the University of Sheffield (UK).

campob@mmv.org